Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big Pharma is facing a looming $236 Billion patent cliff

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jul 10, 2022 12:11pm

249 Views

Post# 34813783

RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

I'm as confident as can be with the science at Oncy, but concerning M&A's & bolt-ons, it seems, at least at the moment, that BP has a preference for gambling on less advanced, less expensive, preclinical or early phase biotechs. For a long time now, I've been concerned with what Matt & Co are asking for acquisition. However, my concern is quelled when I remember that Mr Parsons was brought on for a reason, not just an extra paycheck. He knows Pfizer well.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario